This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

2013 Global life sciences outlook: Optimism tempered by reality in a “new normal”

Optimism tempered by reality in a “new normal”


DOWNLOAD  

Following years of growth and favourable market trends, the global life sciences industry now finds itself facing a challenging “new normal”.

A changing health care landscape, expiring patents and generic competition, pricing pressures, heightened regulatory scrutiny, expansion into emerging markets, increasing alliances and acquisitions, and a persistent economic slowdown are prompting global life sciences companies to adopt new business models designed to counter slowing sales growth and declining profitability, deliver better patient outcomes at lower cost, and position them for success in 2013 and beyond.

To grow in this challenging climate, the global life sciences industry is transitioning away from a primary care, small-molecule-driven sales model towards targeting specialist secondary care indications through the use of high-value biologic therapies in the developed markets (Europe and the U.S.), while also taking a global perspective by marketing branded and off-patent medicines in the fast-growing emerging markets. Cost savings facilitated by mergers and acquisitions are also set to bolster profits.

This report examines the current state of the global life sciences industry, describes the top issues facing stakeholders, provides a snapshot of activity in a number of geographic markets, and suggests considerations for companies as they seek to grow revenue and market share in 2013 and beyond.

Download the attachment to read more.

Stay connected:
More on Deloitte
Learn about our site

SEA-games